One Pager as on October 30, 2026
![]() | Prudent portfolio of investments across companies and sectors. |
![]() | Actively managed by professional fund managers for potential long term capital appreciation. |
![]() | Opportunity to participate in successful businesses through equity market. |
| Sector | MMMCF* | Nifty 500 Multicap 50:25:25 TRI |
| Financial Services | 28.47% | 28.40% |
| Healthcare | 15.83% | 8.46% |
| Capital Goods | 11.43% | 8.72% |
| Oil Gas & Consumable Fuels | 6.16% | 5.64% |
| Metals & Mining | 5.56% | 3.63% |
*Mahindra Manulife Multi Cap Fund
Data as on October 30, 2026
| Security | % to Net Assets |
| Divi's Laboratories Limited | 5.36% |
| ICICI Bank Limited | 3.50% |
| Reliance Industries Limited | 2.98% |
| Multi Commodity Exchange of India Limited | 2.94% |
| BSE Limited | 2.86% |
| HDFC Bank Limited | 2.83% |
| Neuland Laboratories Limited | 2.56% |
| Oil India Limited | 2.54% |
| Adani Enterprises Limited | 2.52% |
| Torrent Pharmaceuticals Limited | 2.29% |
| Total | 30.38% |
| Fresh Additions | Complete Exits |
| Security | Security |
| BSE Limited | Avenue Supermarts Limited |
| Bajaj Finance Limited | Sai Life Sciences Limited |
| TD Power Systems Limited | Max Financial Services Limited |
| Indian Bank | Sun Pharmaceutical Industries Limited |
| Life Insurance Corporation Of India | Union Bank of India |
| Cartrade Tech Limited | Oil & Natural Gas Corporation Limited |
| City Union Bank Limited | Oswal Pumps Limited |
| - | Gokaldas Exports Limited |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Data as on October 30, 2026
| Turnover Ratio (Last 1 year) | 1.15 |
| Standard Deviation | 16.98% |
| Beta | 0.98 |
| Sharpe Ratio# | 0.51 |
| Jenson's Alpha | 0.2487 |
#Risk-free rate assumed to be 5.74% (MIBOR as on 30-10-2026) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on October 30, 2026
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 11-May-17.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Vishal Jajoo is managing this scheme since November 3, 2025. Mr. Neelesh Dhamnaskar is managing this scheme since July 21, 2026. *Based on standard investment of Rs.10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 11-May-17.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Vishal Jajoo manages 6 scheme, Mr. Neelesh
Dhamnaskar manages 7 schemes each of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Note: Performance as on October 30, 2026.
This product is suitable for investors who are seeking*:
• Medium to Long term capital
appreciation.
• Investment predominantly in
Equity and Equity Related Instruments
including derivatives.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
![]() |
||||
![]() |
![]() |
![]() |
![]() |
![]() |